Compare Neurocrine Biosciences Inc (NBIX) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Wendys Co — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while Wendys Co trades at $7.56 (market cap $1.44B). The key difference: Neurocrine Biosciences Inc is far larger — about 11× Wendys Co's market cap, and Wendys Co pays a 3.71% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | WEN | |
|---|---|---|
Market Cap | $15.77B | $1.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $9.89 |
52-Week Low | $123.10 | $6.17 |
Enterprise Value | $15.78B | $5.17B |
Dividend Yield | — | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Wendy's (WEN) trades at $7.61, down 5.23% on the day, reflecting bearish technical signals and negative sentiment following the collapse of Trian's potential take-private bid. The stock shows a low P/E of 11.54 and P/S of 0.66, indicating potential undervaluation, but faces declining net income margins and high debt levels. Recent earnings have consistently beaten expectations, yet U.S. traffic fell 12.5% in 2026, highlighting operational challenges under new CEO Bob Wright's turnaround plan.
The outlook is cautious; while valuation metrics appear attractive and analyst consensus targets $8.13, near-term risks from weak sales, high leverage, and failed M&A speculation outweigh opportunities. Investors should monitor execution of the five-point reset strategy for traffic recovery, but competitive pressures and inconsistent cash flow generation pose significant headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
